IP Library Granted Patent US 12,404,560
Granted Patent B2
US 12,404,560 · App. 17/525,823 · Granted Sep 2, 2025

Airborne pathogen simulants and mobility testing

Inventors: Ulrike W. Hodges (Berkeley, CA); Quin Chou (Pleasanton, CA); Erik Malmstrom (San Jose, CA); Phil M. Arnold (Redwood City, CA)
Assignee: SafeTraces, Inc.
C12Q1/701C12Q1/68C12Q1/6825C12Q1/6851C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,560
App. No.
17/525,823
Filed
Nov 12, 2021
Granted
Sep 2, 2025
Kind
B2
Examiner
LEE, SEUNG H
Art Unit
2876
USPC
435/5
Abstract

Airborne pathogen mobility and the airborne mobility of respiratory droplets, such as saliva, and testing thereof, can be monitored by tracking detectable compounds and measuring concentrations. A display can be presented including a building layout and simulant concentrations released and collected at various locations within a space.

Claims (48)

1. A method of testing and evaluating a building space for possible airborne pathogen travel, the method comprising:

releasing a simulant at a first release location within the building space, wherein the simulant comprises water, a DNA taggant, and a carrier, and wherein the simulant is characterized in having a behavior suitable for simulating human emission of a pathogen;

collecting a portion of released simulant at a first collection location within the building space, wherein the first release location and the first collection location are separated by building infrastructure of the building space and wherein the first release location and the first collection location are such that measurable airflow occurs from the first release location to the first collection location; and

displaying movement of the simulant, comprising:

(a) receiving information of a first amount of the simulant at the first release location and of a second amount of the simulant detected the first collection location; and

(b) generating a report displaying a first graphic element representing the first amount of the simulant at the first release location and displaying a second graphic element representing the second amount of the simulant at the first collection location in a map comprising the first release location and the first collection location.

2. The method of claim 1 , wherein the pathogen is SARS-Cov-2.

3. The method of claim 1 , wherein the carrier comprises polysaccharides, proteins, salt, or a combination thereof.

4. The method of claim 3 , further comprising one or more additional carriers to form a saliva simulant solution containing around 99% H 2 O, and around 1% of a mixture of the polysaccharides, the proteins, the salt, or the combination thereof, and DNA taggants.

5. The method of claim 1 , wherein the simulant comprises dispensed liquid particles that transport through air sized from about 0.01 μm to about 100 μm, formed by binding the DNA taggant to a carrier polysaccharide and/or one or more protein.

6. The method of claim 1 , wherein the map comprises a heat map.

7. The method of claim 1 , wherein the map comprises elements representing simulant concentrations overlaid on a building layout.

8. The method of claim 1 , wherein the simulant has a characteristic that matches or simulates saliva.

9. A method of testing and evaluating a building space for possible airborne pathogen travel, the method comprising:

releasing a simulant at a first release location within the building space, wherein the simulant comprises water, a DNA taggant, and a carrier, and wherein the simulant is characterized in having a behavior suitable for simulating human emission of a pathogen;

collecting a portion of released simulant at a first collection location within the building space, wherein the first release location and the first collection location are separated by building infrastructure of the building space and wherein the first release location and the first collection location are such that measurable airflow occurs from the first release location to the first collection location

mapping a plurality of collection locations;

mapping a plurality of release locations;

releasing a selected DNA taggant at a release location;

collecting droplet and/or aerosol sample at a collection location of the plurality of collection locations; and

quantifying DNA concentrations at collection locations using qPCR.

10. The method of claim 9 , wherein at least some of the plurality of release locations are mobile and simulate dispersing while moving.

11. The method of claim 9 , wherein releasing comprises releasing a plurality of releases using a plurality of DNA taggants or combinations thereof.

12. A method of testing and evaluating a building space for possible airborne pathogen travel, the method comprising:

releasing a simulant at a first release location within the building space, wherein the simulant comprises water, a DNA taggant, and a carrier, and wherein the simulant is characterized in having a behavior suitable for simulating human emission of a pathogen; and

collecting a portion of released simulant at a first collection location within the building space, wherein the first release location and the first collection location are separated by building infrastructure of the building space and wherein the first release location and the first collection location are such that measurable airflow occurs from the first release location to the first collection location,

wherein the simulant has a characteristic that matches or simulates saliva, and wherein the characteristic is an evaporation rate.

13. The method of claim 12 , wherein the pathogen is SARS-Cov-2.

14. The method of claim 12 , wherein the carrier comprises polysaccharides, proteins, salt, or a combination thereof, wherein the simulant comprises dispensed liquid particles that transport through air sized from about 0.01 μm to about 100 μm, formed by binding the DNA taggant to a carrier polysaccharide and/or one or more protein, and wherein one or more additional carriers form a saliva simulant solution containing around 99% H 2 O, and around 1% of a mixture of the polysaccharides, the proteins, the salt, or the combination thereof, and DNA taggants.

15. The method of claim 12 , further comprising:

mapping a plurality of collection locations;

mapping a plurality of release locations;

releasing a selected DNA taggant at a release location;

collecting droplet and/or aerosol sample at a collection location of the plurality of collection locations; and

quantifying DNA concentrations at collection locations using qPCR.

16. The method of claim 15 , wherein at least some of the plurality of release locations are mobile and simulate dispersing while moving.

17. The method of claim 15 , wherein releasing comprises releasing a plurality of releases using a plurality of DNA taggants or combinations thereof.

18. A method of testing and evaluating a building space for possible airborne pathogen travel, the method comprising:

releasing a simulant at a first release location within the building space, wherein the simulant comprises water, a DNA taggant, and a carrier, and wherein the simulant is characterized in having a behavior suitable for simulating human emission of a pathogen; and

collecting a portion of released simulant at a first collection location within the building space, wherein the first release location and the first collection location are separated by building infrastructure of the building space and wherein the first release location and the first collection location are such that measurable airflow occurs from the first release location to the first collection location,

wherein the simulant has a characteristic that matches or simulates emission by a human of a human emission and wherein the characteristic is an evaporation rate of the human emission.

19. The method of claim 18 , wherein the human emission is one or more of a human aerosol emission, a human droplet emission, a human droplet emission followed by at least partial evaporation to become aerosolized, and/or a combination thereof.

20. The method of claim 18 , further comprising:

mapping a plurality of collection locations;

mapping a plurality of release locations;

releasing a selected DNA taggant at a release location;

collecting droplet and/or aerosol sample at a collection location of the plurality of collection locations; and

quantifying DNA concentrations at collection locations using qPCR.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 27, 2025
From: AGILITY CAPITAL III, LLC
To: SAFETRACES, INC.
Reel/Frame 070668/0511 →
SECURITY INTEREST Recorded Jun 21, 2023
From: SAFETRACES, INC.
To: AGILITY CAPITAL III, LLC
Reel/Frame 064010/0737 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY ADDRESS PREVIOUSLY RECORDED AT REEL: 061207 FRAME: 0971. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 6, 2023
From: CHOU, QUIN
To: SAFETRACES, INC.
Reel/Frame 063351/0816 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY ADDRESS PREVIOUSLY RECORDED ON REEL 060849 FRAME 0619. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 2, 2023
From: HODGES, ULRIKE W.; MALMSTROM, ERIK; ARNOLD, PHIL M.
To: SAFETRACES, INC.
Reel/Frame 063294/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2022
From: HODGES, ULRIKE W.; MALMSTROM, ERIK; ARNOLD, PHIL M.
To: SAFETRACES, INC.
Reel/Frame 060849/0619 →
EMPLOYMENT AGREEMENT Recorded Aug 18, 2022
From: CHOU, QUIN
To: SAFETRACES, INC.
Reel/Frame 061207/0971 →
Continuity (4)
Continuation 17165935 · Feb 2, 2021
Provisional Application 63066076 · Aug 14, 2020
Provisional Application 63011176 · Apr 16, 2020
Related Publication 20220177981A1 · Jun 9, 2022
References Cited (107)
US 1913069A · Chance · 1933 [cited by applicant]
US 4593360A · Cocks · 1986 [cited by applicant]
US 6312911B1 · Bancroft et al. · 2001 [cited by applicant]
US 6532835B1 · Saaski et al. · 2003 [cited by applicant]
US 8293535B2 · Farquar et al. · 2012 [cited by applicant]
US 10556032B2 · Zografos et al. · 2020 [cited by applicant]
US 11087888B2 · Chatterjea · 2021 [cited by examiner]
US 11129915B2 · Zografos et al. · 2021 [cited by applicant]
US 20020129523A1 · Hunt · 2002 [cited by applicant]
US 20040166520A1 · Connolly · 2004 [cited by applicant]
US 20050031487A1 · Rosenblatt et al. · 2005 [cited by applicant]
US 20050042604A1 · Tong et al. · 2005 [cited by applicant]
US 20060037222A1 · Hunt et al. · 2006 [cited by applicant]
US 20060111845A1 · Forbis et al. · 2006 [cited by applicant]
US 20090070134A1 · Rodgers · 2009 [cited by applicant]
US 20100159434A1 · Lampotang et al. · 2010 [cited by applicant]
US 20100261193A1 · Webster et al. · 2010 [cited by applicant]
US 20110165569A1 · Macula · 2011 [cited by applicant]
US 20110177539A1 · Sutton et al. · 2011 [cited by applicant]
US 20120112883A1 · Wallace et al. · 2012 [cited by applicant]
US 20130052751A1 · Farquar et al. · 2013 [cited by applicant]
US 20130122807A1 · Tenarvitz et al. · 2013 [cited by applicant]
US 20140046722A1 · Rosenbloom et al. · 2014 [cited by applicant]
US 20140057276A1 · Farquar et al. · 2014 [cited by applicant]
US 20140108039A1 · Rensvold et al. · 2014 [cited by applicant]
US 20140167917A2 · Wallace et al. · 2014 [cited by applicant]
US 20140220576A1 · Macula · 2014 [cited by applicant]
US 20140255984A1 · Sharpin · 2014 [cited by applicant]
US 20140272097A1 · Jung et al. · 2014 [cited by applicant]
US 20140340423A1 · Taylor et al. · 2014 [cited by applicant]
US 20150034309A1 · Blair · 2015 [cited by applicant]
US 20150205985A1 · Jinadatha · 2015 [cited by applicant]
US 20150314026A1 · Mauzerall et al. · 2015 [cited by applicant]
US 20150322426A1 · Zografos et al. · 2015 [cited by applicant]
US 20150361490A1 · Farquar et al. · 2015 [cited by applicant]
US 20160038083A1 · Ding et al. · 2016 [cited by applicant]
US 20160102335A1 · Franciskovich et al. · 2016 [cited by applicant]
US 20160171179A1 · Donofrio et al. · 2016 [cited by applicant]
US 20160188943A1 · Franz · 2016 [cited by applicant]
US 20160306934A1 · Sperry et al. · 2016 [cited by applicant]
US 20160307459A1 · Chestnut et al. · 2016 [cited by applicant]
US 20170038353A1 · Zografos et al. · 2017 [cited by applicant]
US 20170081707A1 · Dillon et al. · 2017 [cited by applicant]
US 20170197002A1 · Dobrinsky et al. · 2017 [cited by applicant]
US 20170322701A1 · Bowman et al. · 2017 [cited by applicant]
US 20170333859A1 · Lind · 2017 [cited by applicant]
US 20180108178A1 · Murugappan et al. · 2018 [cited by applicant]
US 20180126021A1 · Valentine et al. · 2018 [cited by applicant]
US 20180252738A1 · Denney · 2018 [cited by applicant]
US 20180369438A1 · Grossman et al. · 2018 [cited by applicant]
US 20190029002A1 · Kotzer et al. · 2019 [cited by applicant]
US 20190086296A1 · West · 2019 [cited by applicant]
US 20190087533A1 · O'Hara · 2019 [cited by applicant]
US 20190120727A1 · Harding et al. · 2019 [cited by applicant]
US 20190211324A1 · Zografos et al. · 2019 [cited by applicant]
US 20190241982A1 · Hogan et al. · 2019 [cited by applicant]
US 20190318807A1 · O'Hara et al. · 2019 [cited by applicant]
CN 101379188A · 2009 [cited by applicant]
CN 104024426A · 2014 [cited by applicant]
CN 104131008A · 2014 [cited by applicant]
CN 104513863A · 2015 [cited by applicant]
WO 2004063856A2 · 2004 [cited by applicant]
WO 2008083323A9 · 2008 [cited by applicant]
WO 2008137831A1 · 2008 [cited by applicant]
WO 2011163296A2 · 2011 [cited by applicant]
WO 2012037876A1 · 2012 [cited by applicant]
WO 2014164958A1 · 2014 [cited by applicant]
WO 2017049160A2 · 2017 [cited by applicant]
WO WO2017096110A1 · 2017 [cited by examiner]
WO 2019157227A1 · 2019 [cited by applicant]
Pan et al., “Collection, Particle Sizing and Detection of Airborne Viruses,” Journal of Applied Microbiology 127:1596-1611 (2019) [doi=10.1111/jam.14278]. [cited by applicant]
International Search Report issued in PCT Application No. PCT/US2021/027495, mailed on Dec. 8, 2021. [cited by applicant]
Extended European Search Report mailed Apr. 3, 2024, European Patent Application No. 21811937.8, filed Apr. 15, 2021, 7 pages. [cited by applicant]
Singh et al., “Coronavirus-mimicking nanoparticles (CorNPs) in artificial saliva droplets and nanoaerosols: Influence of shape and environmental factors on particokinetics/particle aerodynamics”, Science of Total Enviro… [cited by applicant]
Andrews, “DNA Spray-On Technology Could Revolutionize Food Traceability”, Food Safety News, http://www.foodsafetynews.com/2014/11/dna-laced-spray-technology-could-revolutionize-food-traceability/#.W1kRNNVKjRY, 2014, 2 p… [cited by applicant]
Busta et al., “The Use of Indicators and Surrogate Microorganisms for the Evaluation of Pathogens in Fresh and Fresh-Cut Produce”, Comprehensive Reviews in Food Science and Food Safety, vol. 2 (Supplement), 2003, pp. 17… [cited by applicant]
Bystrykh, “Generalized DNA Barcode Design Based on Hamming Codes”, PLOS One, vol. 7(5):e36852, 2012, 8 pages. [cited by applicant]
Danyluk, “Process Validation: Selection and Use of Surrogates”, University of Florida, Institute of Food and Agricultural Sciences, presentation dated Apr. 2014, 19 pages. [cited by applicant]
European Supplementary Search Report dated Jun. 15, 2018 in European Patent Application No. 15878244.1, 1 page. [cited by applicant]
European Supplementary Search Report dated Feb. 7, 2019 in European Patent Application No. 16833458.9, 1 page. [cited by applicant]
European Supplementary Search Report dated Oct. 1, 2020 in European Patent Application No. 19738614.7, 1 page. [cited by applicant]
Farquar, “DNATrax (DNA Tagged Reagents for Aerosol eXperiments)”, Lawrence Livermore National Laboratory, presentation LLNL-PRES-642415, 2013, retrieved from the Internet at https://ipo.llnl.gov/success/multimedia/dnatr… [cited by applicant]
Galimberti et al., “DNA Barcoding as a New Tool for Food Traceability”, Food Research International, vol. 50(I), 2013, pp. 55-63. [cited by applicant]
Galimberti et al., “DNA Barcoding for Minor Crops and Food Traceability”, Hindawi Publishing Corporation, Advances in Agriculture, vol. 2014, Article ID 831875, 2014, pp. 1-8. [cited by applicant]
Harding et al., “Unique DNA-barcoded Aerosol Test Particles for Studying Aerosol Transport”, Aerosol Science and Technology, vol. 50(5), 2016, pp. 429-435. [cited by applicant]
Hou et al., “Rapid Bioparticle Concentration and Detection by Combining a Discharge Driven Vortex with Surface Enhanced Raman Scattering”, Biomicrofluidics 1, 014106, 2007, pp. 1-13. [cited by applicant]
International Search Report mailed Aug. 12, 2015 in International Patent Application No. PCT/US2015/028880, 3 pages. [cited by applicant]
International Search Report mailed Sep. 8, 2016 in International Patent Application No. PCT/US2016/038083, 2 pages. [cited by applicant]
International Search Report mailed Mar. 15, 2019 in International Patent Application No. PCT/US2019/013069, 2 pages. [cited by applicant]
International Search Report mailed Aug. 9, 2019 in International Patent Application No. PCT/ US2019/029002, 2 pages. [cited by applicant]
Ma et al., “Development of Thermal Surrogate Microorganisms in Ground Beef for In-Plant Critical Control Point Validation Studies”, Journal of Food Protection, vol. 70(4), 2007, pp. 952-957. [cited by applicant]
Naaum, “Novel Methods of Species and Product Authenticity and Traceability Testing Using DNA Analysis for Food and Agricultural Applications”, Doctoral Dissertation, Department of Integrative Biology, University of Guel… [cited by applicant]
Niebuhr et al., “Evaluation of Nonpathogenic Surrogate Bacteria as Process Validation Indicators for [cited by applicant]
Oxford Gene Technology, “DNA Storage and Quality,” Aug. 22, 2011, retrieved from the Internet at http://www.ogt.com/resources/literature/403_dna_storage_and_quality, 5 pages. [cited by applicant]
Puddu et al., “Magnetically Recoverable, Thermostable, Hydrophobic DNA/Silica Encapsulates and Their Application as Invisible Oil Tags” ACS Nano, vol. 8(3), 2014, pp. 2677-2685. [cited by applicant]
Ruther, “Assistive Systems for Quality Assurance by Context-aware User Interfaces in Health Care and Production”, Dissertation, Faculty of Technology, Bielefeld University, 2014, 168 pages. [cited by applicant]
Sharma et al., “Hydrological Tracers Using Nanobiotechnology: Proof of Concept”, Environmental Science and Technology, vol. 46(16), 2012, pp. 8928-8936. [cited by applicant]
Sinclair et al., “A Criteria for Selection of Surrogates Used to Study the Fate and Control of Pathogens in the Environment”, Applied and Environmental Microbiology, vol. 78(6), 2012, pp. 1969-1977. [cited by applicant]
Wan et al., “Modeling the Fate of Expiratory Aerosols and the Associated Infection Risk in an Aircraft Cabin Environment”, vol. 43, 2009, pp. 322-343. [cited by applicant]
Yeater et al., “Effectiveness of Sanitizing Products on Controlling Selected Pathogen Surrogates on Retail Deli Slicers”, Journal of Food Protection, vol. 78(4), 2015, pp. 707-715. [cited by applicant]
International Search Report issued in PCT Application No. PCT/US2021/016065, mailed on May 24, 2021. [cited by applicant]
Kumar et al., “A rapid screening for adulterants in olive oil using DNA barcodes.” Food Chemistry 127.3 (2011): 1335-1341 (Year: 2011), pp. 1336-1341. [cited by applicant]
Leier et al., “Cryptography with DNA binary strands.” Biosystems 57 .1 (2000): 13-22. (Year: 2000), pp. 13-22. [cited by applicant]
Ovissipour et al., “DNA-based surrogate indicator for sanitation verification and predict inactivation of [cited by applicant]
Singh et al., “DNA QR coding for data security using DNA sequence.” International Journal of Information Technology 12.2 (Jan. 18, 2020): 571-576 (Year: 2020), pp. 571-576. [cited by applicant]
Vassou et al., “DNA barcoding for species identification from dried and powdered plant parts: A case study with authentication of the raw drug market samples of Sida cordifolia.” Gene 559.1 (2015): 86-93 (Year:2015), pp… [cited by applicant]
Yaari et al., “Theranostic barcoded nanoparticles for personalized cancer medicine.” Nature communications 7.1 (2016): 13325 (Year: 2016), pp. 1-10. [cited by applicant]